vs
Side-by-side financial comparison of ACADIA PHARMACEUTICALS INC (ACAD) and Federal Realty Investment Trust (FRT). Click either name above to swap in a different company.
Federal Realty Investment Trust is the larger business by last-quarter revenue ($336.0M vs $284.0M, roughly 1.2× ACADIA PHARMACEUTICALS INC). ACADIA PHARMACEUTICALS INC runs the higher net margin — 96.3% vs 38.6%, a 57.7% gap on every dollar of revenue. On growth, ACADIA PHARMACEUTICALS INC posted the faster year-over-year revenue change (9.4% vs 8.7%). Over the past eight quarters, ACADIA PHARMACEUTICALS INC's revenue compounded faster (17.5% CAGR vs 6.5%).
Acadia Pharmaceuticals Inc. is a biopharmaceutical company headquartered in Del Mar, San Diego, California.
Federal Realty Investment Trust is a real estate investment trust that invests in shopping centers in the Northeastern United States, the Mid-Atlantic states, California, and South Florida.
ACAD vs FRT — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $284.0M | $336.0M |
| Net Profit | $273.6M | $129.7M |
| Gross Margin | 90.8% | — |
| Operating Margin | 6.1% | 53.8% |
| Net Margin | 96.3% | 38.6% |
| Revenue YoY | 9.4% | 8.7% |
| Net Profit YoY | 90.3% | 103.5% |
| EPS (diluted) | $1.61 | $1.49 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $336.0M | ||
| Q4 25 | $284.0M | $336.0M | ||
| Q3 25 | $278.6M | $322.3M | ||
| Q2 25 | $264.6M | $311.5M | ||
| Q1 25 | $244.3M | $309.2M | ||
| Q4 24 | $259.6M | $311.4M | ||
| Q3 24 | $250.4M | $303.6M | ||
| Q2 24 | $242.0M | $296.1M |
| Q1 26 | — | $129.7M | ||
| Q4 25 | $273.6M | $129.7M | ||
| Q3 25 | $71.8M | $61.6M | ||
| Q2 25 | $26.7M | $155.9M | ||
| Q1 25 | $19.0M | $63.8M | ||
| Q4 24 | $143.7M | $65.5M | ||
| Q3 24 | $32.8M | $61.0M | ||
| Q2 24 | $33.4M | $112.0M |
| Q1 26 | — | — | ||
| Q4 25 | 90.8% | — | ||
| Q3 25 | 92.2% | — | ||
| Q2 25 | 92.2% | — | ||
| Q1 25 | 91.7% | — | ||
| Q4 24 | 91.6% | — | ||
| Q3 24 | 92.5% | — | ||
| Q2 24 | 92.5% | — |
| Q1 26 | — | 53.8% | ||
| Q4 25 | 6.1% | 53.8% | ||
| Q3 25 | 12.8% | 34.3% | ||
| Q2 25 | 12.2% | 65.1% | ||
| Q1 25 | 7.9% | 35.0% | ||
| Q4 24 | 59.1% | 35.1% | ||
| Q3 24 | 12.6% | 34.9% | ||
| Q2 24 | 12.6% | 53.0% |
| Q1 26 | — | 38.6% | ||
| Q4 25 | 96.3% | 38.6% | ||
| Q3 25 | 25.8% | 19.1% | ||
| Q2 25 | 10.1% | 50.0% | ||
| Q1 25 | 7.8% | 20.6% | ||
| Q4 24 | 55.4% | 21.0% | ||
| Q3 24 | 13.1% | 20.1% | ||
| Q2 24 | 13.8% | 37.8% |
| Q1 26 | — | $1.49 | ||
| Q4 25 | $1.61 | $1.49 | ||
| Q3 25 | $0.42 | $0.69 | ||
| Q2 25 | $0.16 | $1.78 | ||
| Q1 25 | $0.11 | $0.72 | ||
| Q4 24 | $0.86 | $0.74 | ||
| Q3 24 | $0.20 | $0.70 | ||
| Q2 24 | $0.20 | $1.32 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $177.7M | $107.4M |
| Total DebtLower is stronger | — | $5.0B |
| Stockholders' EquityBook value | $1.2B | $3.2B |
| Total Assets | $1.6B | $9.1B |
| Debt / EquityLower = less leverage | — | 1.53× |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $107.4M | ||
| Q4 25 | $177.7M | $107.4M | ||
| Q3 25 | $258.0M | $111.3M | ||
| Q2 25 | $253.6M | $177.0M | ||
| Q1 25 | $217.7M | $109.2M | ||
| Q4 24 | $319.6M | $123.4M | ||
| Q3 24 | $155.1M | $97.0M | ||
| Q2 24 | $177.1M | $103.2M |
| Q1 26 | — | $5.0B | ||
| Q4 25 | — | $5.0B | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | $4.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $3.2B | ||
| Q4 25 | $1.2B | $3.2B | ||
| Q3 25 | $917.3M | $3.2B | ||
| Q2 25 | $822.4M | $3.2B | ||
| Q1 25 | $765.2M | $3.2B | ||
| Q4 24 | $732.8M | $3.2B | ||
| Q3 24 | $577.2M | $3.1B | ||
| Q2 24 | $516.7M | $3.0B |
| Q1 26 | — | $9.1B | ||
| Q4 25 | $1.6B | $9.1B | ||
| Q3 25 | $1.3B | $8.9B | ||
| Q2 25 | $1.2B | $8.6B | ||
| Q1 25 | $1.1B | $8.6B | ||
| Q4 24 | $1.2B | $8.5B | ||
| Q3 24 | $976.9M | $8.5B | ||
| Q2 24 | $914.1M | $8.4B |
| Q1 26 | — | 1.53× | ||
| Q4 25 | — | 1.53× | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | 1.42× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-48.7M | — |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | -0.18× | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-48.7M | $622.4M | ||
| Q3 25 | $74.3M | $147.8M | ||
| Q2 25 | $64.0M | $150.7M | ||
| Q1 25 | $20.3M | $179.0M | ||
| Q4 24 | $40.4M | $574.6M | ||
| Q3 24 | $63.2M | $144.1M | ||
| Q2 24 | $25.0M | $169.7M |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | $73.9M | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $63.2M | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 26.5% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 25.2% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | 0.1% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 0.0% | — | ||
| Q2 24 | — | — |
| Q1 26 | — | — | ||
| Q4 25 | -0.18× | 4.80× | ||
| Q3 25 | 1.03× | 2.40× | ||
| Q2 25 | 2.40× | 0.97× | ||
| Q1 25 | 1.07× | 2.81× | ||
| Q4 24 | 0.28× | 8.77× | ||
| Q3 24 | 1.93× | 2.36× | ||
| Q2 24 | 0.75× | 1.52× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ACAD
| Nuplazid | $174.4M | 61% |
| Daybue | $109.6M | 39% |
FRT
Segment breakdown not available.
